CAR T-cell therapy of solid tumors.

Area of Science:

• Oncology
• Immunology
• Biotechnology

Background:

• Immunotherapy, specifically adoptive cell transfer with chimeric antigen receptor (CAR) T-cells, has shown significant success in treating certain leukemias.
• However, the efficacy of CAR T-cell therapy is limited in most solid cancers, including breast, colon, and lung cancers.

Purpose of the Study:

• This review aims to discuss the current status of CAR T-cell therapy in solid tumors.
• It will explore innovative strategies to overcome the challenges hindering CAR T-cell therapy in solid cancers.
• The review also focuses on methods to enhance the specificity and safety of these therapies.

Main Methods:

• This is a review article, synthesizing current research and clinical findings.
• It examines various approaches being investigated to address the limitations of CAR T-cell therapy in solid tumors.

Main Results:

• Solid tumors present significant barriers to CAR T-cell therapy, including immune suppression and impaired T-cell infiltration.
• Various novel strategies are under investigation to enhance CAR T-cell function and tumor targeting in solid cancers.

Conclusions:

• Overcoming the unique challenges of the tumor microenvironment is crucial for successful CAR T-cell therapy in solid cancers.
• Future research directions focus on improving CAR T-cell specificity, safety, and persistence for broader clinical application.